Jan 08 2026BUSINESS
A New Era for MannKind: What's Next in 2026?
MannKind, a company focused on treating long-term illnesses, had a strong finish to 2025. They acquired another company, scPharmaceuticals, and made over $100 million in their last quarter. This success has set the stage for an exciting 2026, with two major products potentially hitting the market.
reading time less than a minute
